Clinical trial

Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia

Name
PRO17030527
Description
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.
Trial arms
Trial start
2017-09-01
Estimated PCD
2024-08-31
Trial end
2024-08-31
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Lithium Carbonate
See lithium carbonate arm
Arms:
Lithium carbonate
Placebo oral capsule
See placebo arm
Arms:
placebo
Size
80
Primary endpoint
California Verbal Learning Test II
At baseline and annually for 2 years
Brief Visuospatial Memory Test - Revised
At baseline and annually for 2 years
NIH Toolbox
At baseline and annually for 2 years
Preclinical Alzheimer Cognitive Composite composed of Memory and other cognitive tests
At baseline and annually for 2 years
GSK-3β activity
At baseline and annually for 2 years
Brain-derived Neurotrophic Factor
At baseline and annually for 2 years
Change from baseline brain volume values over 2 years as measured by structural imaging (7T MRI)
At baseline and annually for 2 years
Eligibility criteria
Inclusion Criteria: 1. 60 years or older 2. Diagnosis of Mild Cognitive Impairment Exclusion Criteria: 1. Major psychiatric illness (mild psychiatric illness may be included) 2. Major neurologic illness (e.g., multiple sclerosis) 3. Contraindication to lithium (e.g., renal insufficiency) 4. Unable to complete neuropsychological testing due to non-remediable impairment (e.g., blindness)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Longitudinal, randomized, double-blind, placebo-controlled experimental trial', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Participants, investigators (who will also be prescribers/care providers), and both clinical and cognitive raters will be blind to treatment. A non-blind physician not providing care or ratings will receive real and generate false blood levels to communicate to other investigators for the purpose of titration of the lithium/placebo. Measures for emergency unblinding will be available as well for safety.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 80, 'type': 'ACTUAL'}}
Updated at
2024-05-09

1 organization

2 products

1 indication

Product
Placebo